Nuvectis Pharma Inc (NVCT)

Nov 21, 2024

Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges - Investing.com

Nov 21, 2024

Nov 21, 2024

Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock By Investing.com - Investing.com Australia

Nov 21, 2024

Nov 21, 2024

Ron Bentsur Buys Handful Of Shares In Nuvectis Pharma - Simply Wall St

Nov 21, 2024

Nov 21, 2024

Insider Buying: Nuvectis Pharma Inc (NVCT) Chairman & CEO Acquires Shares - GuruFocus.com

Nov 21, 2024

Nov 20, 2024

Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock - Investing.com

Nov 20, 2024

Nov 18, 2024

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 20,000 Shares - MarketBeat

Nov 18, 2024

Nov 18, 2024

Nuvectis pharma chairman buys $98,400 in common stock By Investing.com - Investing.com Canada

Nov 18, 2024

Nov 18, 2024

Nuvectis pharma chairman buys $98,400 in common stock - Investing.com

Nov 18, 2024

Nov 15, 2024

Vitalli ends work on Daewoong asset; Alector’s $50M loan - Endpoints News

Nov 15, 2024

Nov 15, 2024

Nuvectis Pharma reports data from Phase 1b study of NXP800 - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort - The Globe and Mail

Nov 14, 2024

Nov 14, 2024

500: Something went wrong - Investing.com Canada

Nov 14, 2024

Nov 14, 2024

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug - Yahoo Finance

Nov 14, 2024

Nov 14, 2024

NVCT stock touches 52-week low at $5.05 amid market fluctuations - Investing.com India

Nov 14, 2024

Nov 14, 2024

Nuvectis sinks after early-stage data for ovarian cancer therapy - MSN

Nov 14, 2024

Nov 14, 2024

U.S. Stock market: Nuvectis Pharma declined by 40.58% while Sow Good was down by 55.30% during mid day trading - Business Upturn

Nov 14, 2024

Nov 14, 2024

Nuvectis stock sinks on data for cancer drug (NVCT:NASDAQ) - Seeking Alpha

Nov 14, 2024

Nov 14, 2024

Nuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer Study - MarketWatch

Nov 14, 2024

Nov 14, 2024

Nuvectis Pharma Inc trading resumes - TipRanks

Nov 14, 2024

Nov 14, 2024

U.S. Stock market: Nuvectis Pharma saw a sharp decline of 53.89% while AgEagle Aerial Systems surged by 133.74% in early trading - Business Upturn

Nov 14, 2024

Nov 14, 2024

Nuvectis Pharma Reports Encouraging NXP800 Interim Data - GlobeNewswire

Nov 14, 2024

Nov 14, 2024

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase - The Bakersfield Californian

Nov 14, 2024

Nov 14, 2024

Nuvectis Pharma's NXP800 Shows Promise in Phase 1b Cancer Trial, New Dosing Success | NVCT Stock News - StockTitan

Nov 14, 2024

Nov 14, 2024

Trading (NVCT) With Integrated Risk Controls - Stock Traders Daily

Nov 14, 2024

Nov 14, 2024

Nuvectis Pharma (NASDAQ:NVCT) Announces Third Quarter 2024 Financial Results and Business Updates - Defense World

Nov 14, 2024

Nov 13, 2024

Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance

Nov 13, 2024

Nov 11, 2024

Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - MSN

Nov 11, 2024

Nov 08, 2024

Nuvectis Pharma's VP Michael Carson sells $22.5k in stock - Investing.com

Nov 08, 2024

Nov 08, 2024

Nuvectis Pharma's VP Michael Carson sells $22.5k in stock By Investing.com - Investing.com UK

Nov 08, 2024

Nov 08, 2024

FY2024 EPS Estimates for Nuvectis Pharma Raised by Analyst - Defense World

Nov 08, 2024

Nov 07, 2024

FY2024 EPS Estimate for Nuvectis Pharma Increased by Analyst - MarketBeat

Nov 07, 2024

Nov 07, 2024

Analysts Offer Predictions for Nuvectis Pharma Q1 Earnings - Defense World

Nov 07, 2024

Nov 06, 2024

Roth Capital Comments on Nuvectis Pharma Q1 Earnings - MarketBeat

Nov 06, 2024

Nov 05, 2024

Nuvectis Pharma Reports Improved Q3 Financials and Clinical Progress - TipRanks

Nov 05, 2024

Nov 05, 2024

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire

Nov 05, 2024

Nov 03, 2024

Trend Tracker for (NVCT) - Stock Traders Daily

Nov 03, 2024

Oct 28, 2024

Nuvectis Pharma's NXP900 Shows Promise in NSCLC Treatment, NXP800 Data Update Anticipated - Vancity Buzz

Oct 28, 2024

Oct 28, 2024

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - Business Wire

Oct 28, 2024

Oct 23, 2024

NVCTNuvectis Pharma, Inc. Latest Stock News & Market Updates - StockTitan

Oct 23, 2024

Oct 23, 2024

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times

Oct 23, 2024

Oct 23, 2024

Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire

Oct 23, 2024

Oct 20, 2024

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Oct 20, 2024

Oct 13, 2024

Marshall Wace LLP Has $214,000 Stock Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World

Oct 13, 2024

Oct 07, 2024

Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - The Manila Times

Oct 07, 2024

Oct 02, 2024

Learn to Evaluate (NVCT) using the Charts - Stock Traders Daily

Oct 02, 2024

Sep 24, 2024

Here's Why We're Watching Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation - Yahoo Finance

Sep 24, 2024

Sep 21, 2024

(NVCT) Trading Advice - Stock Traders Daily

Sep 21, 2024

Sep 19, 2024

Industry Update: 3 Exciting Precision Oncology Players to Watch - openPR

Sep 19, 2024

Sep 18, 2024

A new trading data show Nuvalent Inc (NUVL) is showing positive returns. - SETE News

Sep 18, 2024

Sep 18, 2024

What's Going On With Nuvve Stock? - Benzinga

Sep 18, 2024

Sep 18, 2024

Rhumbline Advisers Has $3.18 Million Position in NVE Co. (NASDAQ:NVEC) - Defense World

Sep 18, 2024